Novel therapies for alzheimer's disease: Potentially disease modifying drugs

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The two major neuropathologic hallmarks of Alzheimer's disease (AD) are extracellular Amyloid beta (A plaques and intracellular neurofibrillary tangles (NFTs). Several additional pathogenic mechanisms likely play a role in the pathogenesis of the disease, including inflammation oxidative damage ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above mentioned altered mechanisms. Conversely to symptomatic drugs available to date, these new compounds are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. Some of them are under clinical testing, others are in preclinical phases of development. In this chapter, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update of potentially disease-modifying drugs under testing.

Original languageEnglish
Title of host publicationAlzheimer's Disease Research Compendium
PublisherNova Science Publishers, Inc.
Pages73-96
Number of pages24
ISBN (Print)9781622575107
Publication statusPublished - Jan 1 2013

Fingerprint

Alzheimer Disease
Pharmaceutical Preparations
Neurofibrillary Tangles
Amyloid
Therapeutics
Cholesterol
Ions
Inflammation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Galimberti, D., Fenoglio, C., & Scarpini, E. (2013). Novel therapies for alzheimer's disease: Potentially disease modifying drugs. In Alzheimer's Disease Research Compendium (pp. 73-96). Nova Science Publishers, Inc..

Novel therapies for alzheimer's disease : Potentially disease modifying drugs. / Galimberti, Daniela; Fenoglio, Chiara; Scarpini, Elio.

Alzheimer's Disease Research Compendium. Nova Science Publishers, Inc., 2013. p. 73-96.

Research output: Chapter in Book/Report/Conference proceedingChapter

Galimberti, D, Fenoglio, C & Scarpini, E 2013, Novel therapies for alzheimer's disease: Potentially disease modifying drugs. in Alzheimer's Disease Research Compendium. Nova Science Publishers, Inc., pp. 73-96.
Galimberti D, Fenoglio C, Scarpini E. Novel therapies for alzheimer's disease: Potentially disease modifying drugs. In Alzheimer's Disease Research Compendium. Nova Science Publishers, Inc. 2013. p. 73-96
Galimberti, Daniela ; Fenoglio, Chiara ; Scarpini, Elio. / Novel therapies for alzheimer's disease : Potentially disease modifying drugs. Alzheimer's Disease Research Compendium. Nova Science Publishers, Inc., 2013. pp. 73-96
@inbook{7b48be664476451c89ed50959ca89909,
title = "Novel therapies for alzheimer's disease: Potentially disease modifying drugs",
abstract = "The two major neuropathologic hallmarks of Alzheimer's disease (AD) are extracellular Amyloid beta (A plaques and intracellular neurofibrillary tangles (NFTs). Several additional pathogenic mechanisms likely play a role in the pathogenesis of the disease, including inflammation oxidative damage ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above mentioned altered mechanisms. Conversely to symptomatic drugs available to date, these new compounds are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. Some of them are under clinical testing, others are in preclinical phases of development. In this chapter, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update of potentially disease-modifying drugs under testing.",
author = "Daniela Galimberti and Chiara Fenoglio and Elio Scarpini",
year = "2013",
month = "1",
day = "1",
language = "English",
isbn = "9781622575107",
pages = "73--96",
booktitle = "Alzheimer's Disease Research Compendium",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Novel therapies for alzheimer's disease

T2 - Potentially disease modifying drugs

AU - Galimberti, Daniela

AU - Fenoglio, Chiara

AU - Scarpini, Elio

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The two major neuropathologic hallmarks of Alzheimer's disease (AD) are extracellular Amyloid beta (A plaques and intracellular neurofibrillary tangles (NFTs). Several additional pathogenic mechanisms likely play a role in the pathogenesis of the disease, including inflammation oxidative damage ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above mentioned altered mechanisms. Conversely to symptomatic drugs available to date, these new compounds are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. Some of them are under clinical testing, others are in preclinical phases of development. In this chapter, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update of potentially disease-modifying drugs under testing.

AB - The two major neuropathologic hallmarks of Alzheimer's disease (AD) are extracellular Amyloid beta (A plaques and intracellular neurofibrillary tangles (NFTs). Several additional pathogenic mechanisms likely play a role in the pathogenesis of the disease, including inflammation oxidative damage ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above mentioned altered mechanisms. Conversely to symptomatic drugs available to date, these new compounds are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. Some of them are under clinical testing, others are in preclinical phases of development. In this chapter, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update of potentially disease-modifying drugs under testing.

UR - http://www.scopus.com/inward/record.url?scp=84933035780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933035780&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84933035780

SN - 9781622575107

SP - 73

EP - 96

BT - Alzheimer's Disease Research Compendium

PB - Nova Science Publishers, Inc.

ER -